CompanyGraph
Carsgen Therapeutics Holdings Limited
2171 · HKEX · China
Price data from its CRTHF listing on OTC, quoted in USD
carsgen.comFinancials as of FY2025
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $18.64M, lower than 95% of all stocks globally
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
9.59BHKD1.22B · vs all stocks (USD)
Revenue (TTM)
146.24MHKD18.64M · vs all stocks (USD)
Profit Margin
-77.88%vs Biotechnology peers
Beta
0.2240xvs all stocks
52-Week Change
-29.65%vs all stocks
Market Capitalization
9.59BHKD1.22B · vs all stocks (USD)
Enterprise Value
7.77BHKD991.06M · vs all stocks (USD)
Forward P/E
6.28xvs Biotechnology peers
Price to Sales (TTM)
65.25xvs Biotechnology peers
Price to Book (MRQ)
8.50xvs Biotechnology peers
Enterprise to Revenue
53.16xvs Biotechnology peers
Enterprise to EBITDA
-32.76xvs Biotechnology peers
Profit Margin
-77.88%vs Biotechnology peers
Operating Margin
-116.27%vs Biotechnology peers
Return on Assets (TTM)
-9.61%vs Biotechnology peers
Return on Equity (TTM)
-11.21%vs Biotechnology peers
Revenue (TTM)
146.24MHKD18.64M · vs all stocks (USD)
Revenue per Share (TTM)
0.2280HKDUpdated Aug 19, 2026Quarterly Revenue Growth
125.80%vs Biotechnology peers
Gross Profit (TTM)
93.04MHKD11.86M · vs all stocks (USD)
EBITDA (TTM)
-237.30MHKD-30.25M · vs all stocks (USD)
Net Income (TTM)
-113.89MHKD-14.52M · vs all stocks (USD)
Operating Cash Flow (TTM)
-275.70MHKD-35.15M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-150.33MHKD-19.17M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00HKDUpdated Aug 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Minority Interest (Equity)
-3.98MCNYFY2025 · Dec 31, 2025EPS (Basic)
-0.1800CNYFY2025 · Dec 31, 2025EPS (Diluted)
-0.1800CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
552.06MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
552.06MSharesFY2025 · Dec 31, 2025Operating Cash Flow
-114.48MCNYFY2025 · Dec 31, 2025Free Cash Flow
-119.61MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
1.12BCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-102.91MCNYFY2025 · Dec 31, 2025Stock-based Compensation
25.28MCNYFY2025 · Dec 31, 2025Other Non-cash Items
-9.90MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
219.00KCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-27.18MCNYFY2025 · Dec 31, 2025Capital Expenditures
-5.13MCNYFY2025 · Dec 31, 2025Net Intangibles (CF)
-1.00MCNYFY2025 · Dec 31, 2025Purchase of Investments
-1.66BCNYFY2025 · Dec 31, 2025Sale of Investments
1.66BCNYFY2025 · Dec 31, 2025Other Investing Activity
600.00KCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-4.78MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
0.00CNYFY2025 · Dec 31, 2025Long-term Debt Payments
-89.00MCNYFY2025 · Dec 31, 2025Common Stock Repurchase
-115.28MCNYFY2025 · Dec 31, 2025Other Financing Charges
80.00MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-95.23MCNYFY2025 · Dec 31, 2025Shares Outstanding
546.16MSharesUpdated Aug 19, 2026Float Shares
349.05MSharesUpdated Aug 19, 2026% Held by Insiders
36.68%vs all stocks
% Held by Institutions
4.37%vs all stocks
Total Cash (MRQ)
1.31BHKD166.81M · vs all stocks (USD)
Total Cash per Share (MRQ)
2.09HKDUpdated Aug 19, 2026Total Debt (MRQ)
71.20MHKD9.08M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0785xvs Biotechnology peers
Current Ratio (MRQ)
5.73xvs Biotechnology peers
Book Value per Share (MRQ)
1.69HKDUpdated Aug 19, 2026Total Assets
1.29BCNY191.62M · vs all stocks (USD)
Total Current Assets
1.18BCNYFY2025 · Dec 31, 2025Total Liabilities
512.80MCNYFY2025 · Dec 31, 2025Total Non-current Assets
114.05MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
307.34MCNYFY2025 · Dec 31, 2025Total Current Liabilities
205.46MCNYFY2025 · Dec 31, 2025Cash
1.11BCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
1.11BCNYFY2025 · Dec 31, 2025Accounts Receivable
15.55MCNYFY2025 · Dec 31, 2025Inventory
7.14MCNYFY2025 · Dec 31, 2025Short-term Debt
12.84MCNYFY2025 · Dec 31, 2025Long-term Debt
48.34MCNYFY2025 · Dec 31, 2025Common Stock (Book)
1.00KCNYFY2025 · Dec 31, 2025Retained Earnings
-9.09BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
779.34MCNY115.58M · vs all stocks (USD)
Treasury Stock
0.00CNYFY2025 · Dec 31, 202552-Week Low
10.87HKDUpdated Aug 19, 202652-Week High
28.60HKDUpdated Aug 19, 202652-Week Change
-29.65%vs all stocks
Beta
0.2240xvs all stocks
50-Day MA
14.98HKDUpdated Aug 19, 2026200-Day MA
16.57HKDUpdated Aug 19, 2026Avg 10-Day Volume
2.51MSharesUpdated Aug 19, 2026Avg 30-Day Volume
2.84MSharesUpdated Aug 19, 2026Diluted EPS (TTM)
-0.2100HKDUpdated Aug 19, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $18.64M, lower than 95% of all stocks globallySignificant
Revenue (USD): 18,644,510.126Global P5: 30,274,777.221
Market cap is $1.22B, above the global median of $1.15BNotable
Market cap (USD): 1,222,883,052.048Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
Alpha Tau Medical Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Kissei Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Artivion Inc.
Tier 1ProductionApproval-Gated PipelineRule
Viyash Scientific Limited
Tier 1ProductionApproval-Gated PipelineRuleFlow
Sequent Scientific Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Yizhong Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Xianju Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Beijing Wandong Medical Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Guangdong Taienkang Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hubei Hongyuan Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule